The goal of this clinical trial is to evaluate the effectiveness of PRaG-1 in improving CD8+ lymphocytopenia in patients with solid tumors who are tumor-free for more than six months after completing radiotherapy and/or chemotherapy. It will also assess the safety of PRaG-1 Cordycepin in these patients. The main questions it aims to answer are:
Does PRaG-1 increase CD8+ lymphocyte counts by more than 25% in this patient population? Does the effect of PRaG-1 maintain when treatment is discontinued? What are the safety and tolerability profiles of PRaG-1 during and after the treatment period? Participants will receive open-label PRaG-1 (one tablet in the morning and one in the evening) for 14 days, and those who show a response (CD8+ lymphocytes increase by more than 25%) will enter a 14-day randomized withdrawal period, where they will be assigned to continue PRaG-1 or switch to a placebo.
Throughout the study, participants will:
Have their peripheral blood lymphocyte subpopulations tested at baseline and on Days 7 and 14 Undergo safety monitoring for adverse events according to CTCAE 5.0 criteria Provide information on their quality of life during the treatment period Researchers will compare the outcomes of those who continue PRaG-1 to those who receive a placebo to determine if the observed improvement in CD8+ lymphocytes is sustained, which would indicate that the drug is effective in maintaining immune response.

Start Date01 Dec 2025

Sponsor / Collaborator

Second Affiliated Hospital of Soochow University

NCT07002502

/ Not yet recruitingPhase 2IIT

Immune Modulation and Efficacy Assessment of PRaG-1 in Patients With Advanced Solid Malignancies: A Prospective, Multicenter, Open-Label Clinical Trial

The study is a single-center, prospective, single-arm, Phase II clinical trial. Eligible patients with advanced solid malignant tumors will sign the informed consent form and undergo screening for enrollment. After enrollment, patients will receive oral administration of "PRaG-1" twice daily (morning and evening) for a total of 10 days. Peripheral blood lymphocyte tests will be performed before treatment, on day 5 post-treatment, and at the conclusion of treatment.

Start Date15 Jun 2025

Sponsor / Collaborator

Second Affiliated Hospital of Soochow University

ChiCTR2400088428

/ Not yet recruitingEarly Phase 1IIT

Clinical study on the safety and preliminary efficacy of biosynthetic cordycepin in the treatment of patients with pancarcinogenic advanced solid tumors treated with capecitabine monotherapy or combination chemotherapy due to fatigue

Start Date01 Jul 2024

Sponsor / Collaborator

Shanghai Sixth People's Hospital

100 Clinical Results associated with Cordycepin

100 Translational Medicine associated with Cordycepin

100 Patents (Medical) associated with Cordycepin

1,943

Literatures (Medical) associated with Cordycepin

01 Mar 2026·BIORESOURCE TECHNOLOGY

Pheromone-mediated quorum sensing enables dynamic regulation of cordycepin biosynthesis in Cordyceps militaris

Article

Author: Chen, Long ; Yang, Yang ; Chen, Jianshu ; Yang, Shengli ; Zhang, Qingyang

Cordycepin is a nucleoside compound with broad pharmacological activities, whose biosynthesis is tightly regulated by multilayered metabolic mechanisms. Dynamic regulation strategies allow for precise modulation of target product synthesis while maintaining cell growth, thus overcoming the limitations of static control. In this study, a pheromone-mediated quorum sensing (QS) system was reconstructed in Cordyceps militaris to achieve signal-responsive regulation of cordycepin biosynthesis. Phylogenetic and conserved domain analyses revealed that the pheromone receptor PreB and transcription factor SteA of C. militaris share structural homology with Saccharomyces cerevisiae Ste2 and Ste12, indicating potential functional compatibility across species. The synthetic circuit composed of α-pheromone (mfα1) and the pheromone-responsive promoter P_FUS1 exhibited effective signal-responsive activity in C. militaris. Additionally, placing mfα1 expression under the control of the tryptophan-responsive promoter P_ARO9 enabled cell-density-dependent dynamic regulation. This system specifically activated the key biosynthetic genes cns1 and cns2 at high cell density, resulting in a cordycepin titer of 226.5 mg/L, reflecting a 175.9 % increase compared with the wild type. Through 2A-peptide-mediated multigene co-expression and precursor supply engineering (co-expression of cns1 and nt5e), the cordycepin yield was further elevated to 447.9 mg/L, marking a 445.3 % improvement. This work provides a novel dynamic regulation strategy for efficient cordycepin biosynthesis in C. militaris and lays the groundwork for the development of synthetic biology tools in medicinal fungi.

01 Mar 2026·CELLULAR SIGNALLING

Cordycepin alleviates sepsis-induced cardiomyopathy by attenuating mitochondrial oxidative stress and apoptosis through modulation of the PI3K/Akt/mTOR pathway

Article

Author: Ma, Haoli ; Wang, Yijie ; Yu, Qian ; Yang, Feihong ; Liu, Zilin ; Jiang, Cheng ; Li, Gang ; Yu, Jiangtao ; Chen, Ling

OBJECTIVE:

Sepsis-induced cardiomyopathy (SICM) is a frequent and life-threatening complication of sepsis, characterized by acute cardiac dysfunction and high mortality, yet no specific therapy is currently available. Cordycepin (COR), a natural bioactive compound, has been reported to exert anti-inflammatory and cardioprotective effects; however, its role and underlying mechanisms in SICM remain unclear.

METHODS:

SICM was established in mice by intraperitoneal lipopolysaccharide (LPS) injection or cecal ligation and puncture (CLP). In vitro, HL-1 cells were treated with cytokine mixtures. COR was administered as a pre-treatment in both models. Cardiac function and myocardial injury were evaluated by echocardiography, histopathology, and biochemical assays. Transcriptome sequencing was performed to identify potential pathways, followed by validation using Western blotting and immunofluorescence. Mitochondrial function and cell death were assessed using CCK-8, flow cytometry, JC-1 staining, MitoTracker labeling, and transmission electron microscopy.

RESULTS:

COR markedly attenuated myocardial injury induced by LPS, CLP, and cytokine stimulation. Compared with the model group, COR improved cardiac function, increased 7-day survival, and reduced myocardial inflammatory responses. Transcriptomic profiling implicated PI3K/Akt/mTOR signaling, and subsequent in vivo and in vitro experiments supported pathway activation by COR. Mechanistically, COR restored mitochondrial homeostasis and alleviated oxidative stress, evidenced by decreased ROS and MDA and increased SOD activity, while enhancing mitochondrial membrane potential and ATP production. COR also suppressed cardiomyocyte apoptosis, reflected by reduced Bax expression and decreased ratios of Cleaved Caspase-3/Caspase-3 and Cleaved Caspase-9/Caspase-9, along with increased Bcl-2 expression.

CONCLUSION:

COR mitigates inflammation, oxidative stress, and cardiomyocyte apoptosis in SICM via modulation of the PI3K/Akt/mTOR pathway, thereby attenuating myocardial injury and improving cardiac function. Collectively, these findings indicate that COR may serve as a potential novel therapeutic agent for the management of SICM.

01 Feb 2026·JOURNAL OF BASIC MICROBIOLOGY

Predictive Modeling of Cordycepin Content in Cordyceps militaris Using Machine Learning Based on Cultivation Conditions

Article

Author: Yang, Jae‐Kyung ; Kim, Hyeon Cheol ; Ha, Si Young

ABSTRACT:

Cordycepin, a nucleoside analog derived from Cordyceps militaris , is a bioactive compound with potent pharmacological properties and growing relevance in functional food and pharmaceutical industries. However, its production is highly variable depending on cultivation conditions, making real‐time and scalable prediction essential for efficient process control. This study aimed to develop a machine learning‐based predictive model to estimate cordycepin content based on measurable cultivation parameters. Three machine learning algorithms—XGBoost, Random Forest, and Support Vector Machine—were trained using experimental data encompassing environmental and nutritional factors. Model validation was conducted using Tropsha's statistical criteria, and model explainability was achieved through SHAP analysis. A user‐friendly GUI was also developed for real‐time prediction and application. Among the models, XGBoost demonstrated the highest performance with a cross‐validated Q² of 0.9087 and an R² of 0.9544, satisfying all statistical requirements for reliability. SHAP analysis identified light wavelength and carbon/nitrogen ratio as the most influential factors in cordycepin biosynthesis. The developed GUI enables end‐users to input cultivation conditions and receive immediate predictions, facilitating data‐driven decision‐making. This approach offers a scalable and interpretable framework for optimizing bioactive compound production in edible fungi, with potential application in smart bioprocessing and precision fermentation.

News (Medical) associated with Cordycepin

05 Jan 2026

·www.einpresswire.com

Revolutionary Breakthrough - Insulin created from Black Soldier Fly at Half the Cost of Synthetic Insulin

Patented Green Extraction Technology Transforms Black Soldier Fly Waste Into Pure Insulin at 50% of Synthetic Insulin Cost Half-price natural Insulin is finally within reach, thanks to generational scientist and thought leader, Dr. Abhinav Chauhan.” — Stephen Nice JOHNSON CITY, TN, UNITED STATES, January 5, 2026 / EINPresswire.com / -- Contact: Stephen Nice President, Shield Nutraceuticals, Inc. Phone: 423-202-6145 Email: steve@shieldnutra.com Address: 2109 West Market St., Johnson City, TN 37604 Company Websites: Shield Nutraceuticals: https://shieldnutra.com Chitosan Global: https://chitosanglobal.com REVOLUTIONARY BREAKTHROUGH: Dr. Abhinav Chauhan's Green Extraction Technology Transforms Black Soldier Fly Waste Into Insulin , Chitosan, Melanin , and other High-Value Pharmaceutical Biomaterials Promecens Entosystems Partners with Shield Nutraceuticals' Chitosan Global Division to Commercialize Game-Changing Sustainable Biotechnology Platform Worth $150+ Billion Market Opportunity PUNE, India / JOHNSON CITY, TN – January 1, 2026 – In a groundbreaking development that could revolutionize multiple industries, Dr. Abhinav Chauhan of Promecens Entosystems Private Limited has successfully developed and patented an innovative green extraction technology that transforms Black Soldier Fly (BSF) into five highly purified, commercially viable biomaterials: pure insulin, cordycepin, 99.9% pure eumelanin, antimicrobial peptides, and advanced chitosan. This breakthrough technology, incubated at the prestigious CDFD Technology Incubator under the Department of Biotechnology, Government of India, represents the world's first industrial-scale, environmentally sustainable method for extracting these high-value compounds from insect biomass using green chemistry principles. STRATEGIC U.S. PARTNERSHIP ACCELERATES GLOBAL COMMERCIALIZATION Shield Nutraceuticals, Inc. of Johnson City, Tennessee, led by Steve Nice, has established Chitosan Global as the official U.S. marketing arm of Promecens Entosystems. This strategic partnership positions the revolutionary biomaterials technology for rapid commercialization across North American markets. "We recognized immediately that Dr. Chauhan's technology represents the most significant breakthrough in sustainable biotechnology we've encountered," said Steve Nice, President of Shield Nutraceuticals and Chitosan Global. "The purity levels and cost advantages are unprecedented, positioning these materials to capture significant market share across pharmaceutical, electronics, and agricultural industries." MARKET-DISRUPTING INNOVATION ADDRESSES GLOBAL CHALLENGES The technology addresses critical supply chain vulnerabilities and sustainability challenges across pharmaceutical, biotechnology, electronics, and agricultural industries with a combined total addressable market exceeding $150 billion by 2030. "This is not just an incremental improvement—it's a paradigm shift that transforms agricultural waste into pharmaceutical gold," said Dr. Abhinav Chauhan, Founder and CEO of Promecens Entosystems. "Our patent-pending green extraction process achieves unprecedented purity levels while reducing production costs by 60-85% compared to synthetic alternatives, all while maintaining complete environmental sustainability." FIVE BREAKTHROUGH BIOMATERIALS WITH IMMEDIATE COMMERCIAL APPLICATIONS 1. Pure BSF-Derived Insulin • Market Impact: Addresses the $41.8 billion global insulin market with 70-85% cost reduction • Applications: Diabetes treatment, cultivated meat production (reduces cell culture media costs by 95%) • Advantage: Enhanced thermal stability crucial for developing countries 2. Pharmaceutical-Grade Cordycepin • Market Impact: Targets the rapidly growing $98.3 million cordycepin market (CAGR: 8.1%) • Applications: Cancer treatment (Phase II clinical trials ongoing), antiviral therapy, anti-diabetic treatment • Breakthrough: First commercial-scale extraction from BSF achieving pharmaceutical-grade purity 3. 99.9% Pure Eumelanin • Market Impact: Premium positioning in the $2.1 billion melanin market (CAGR: 9.8%) • Applications: Bioelectronics, organic semiconductors, cosmetics UV protection, medical devices • Innovation: Superior to conventional melanin with thermal stability up to 350°C • Currently Available: Through Chitosan Global with pricing at $480-$390 per gram depending on volume 4. Advanced Antimicrobial Peptides (AMPs) • Market Impact: Captures share of the $2.2 billion AMP market (CAGR: 16.5%) by 2034 • Applications: Antibiotic-resistant bacteria treatment, food preservation, agricultural protection • Critical Need: Addresses 35,000 annual deaths in US from antibiotic-resistant infections 5. Medical-Grade Chitosan • Market Impact: Targets the $8.1 billion chitosan market (CAGR: 17.8%) • Applications: Drug delivery systems, wound healing (FDA-approved applications), tissue engineering • Performance: 90% drug loading efficiency with 72-hour controlled release ENVIRONMENTAL AND ECONOMIC IMPACT The revolutionary green chemistry approach: • Eliminates toxic solvents traditionally used in biomaterial extraction • Reduces carbon footprint by 70% compared to synthetic production methods • Transforms agricultural waste into high-value products, supporting circular economy principles • Achieves industrial-scale production with monthly capacity up to 4,000 grams for premium products TIMING ALIGNS WITH MARKET ACCELERATION The technology launch coincides with unprecedented market dynamics: • Biotechnology sector recovery: Venture funding continued strong growth through 2025 • Natural biomaterials surge: Market valued at $113.99 billion in 2024, projected to reach $251.99 billion by 2031 (CAGR: 12.0%) • Sustainability mandate: 30% of new skincare products in 2023-2024 incorporated natural melanin as UV protection COMPETITIVE ADVANTAGES ESTABLISH MARKET LEADERSHIP Dr. Chauhan's proprietary technology offers: 1. Patent Protection: Exclusive intellectual property rights secured 2. Scalability: Demonstrated industrial-scale production capabilities 3. Quality Consistency: >99.9% purity levels with batch-to-batch reliability 4. Cost Leadership: 60-85% lower production costs than traditional methods 5. Regulatory Pathway: GRAS status potential accelerates market entry ADDRESSING CRITICAL GLOBAL HEALTHCARE NEEDS The technology directly addresses several critical challenges: • Antibiotic Resistance Crisis: AMPs show minimal resistance development • Diabetes Epidemic: Cost-effective insulin production for global access • Cancer Treatment: Natural cordycepin as adjunct therapy • Sustainable Electronics: Biocompatible materials for next-generation devices FORWARD-LOOKING STATEMENTS AND MARKET PROJECTIONS Industry analysts project the sustainable biotechnology sector will experience unprecedented growth, with the global biotechnology market expected to reach $5.71 trillion by 2034. Dr. Chauhan's technology is positioned to capture significant market share across multiple high-growth segments. ABOUT PROMECENS ENTOSYSTEMS PRIVATE LIMITED Founded by Dr. Abhinav Chauhan and incubated at Venture Center (NCL Innovation Park), 100, NCL Innovation Park, Dr. Homi Bhabha Road, Pashan, Pune - 411008, Maharashtra, India, and CDFD Technology Incubator, Hyderabad, India. Promecens Entosystems is a deep‑technology biomaterials company focused on sustainable extraction of high-value biomaterials from insect biomass using green chemistry principles. The company holds proprietary patents for revolutionary extraction technologies that transform Black Soldier Fly Larvae into pharmaceutical-grade compounds. ABOUT SHIELD NUTRACEUTICALS, INC. AND CHITOSAN GLOBAL Shield Nutraceuticals, Inc., headquartered in Johnson City, Tennessee, is a leading provider of high-quality nutraceutical ingredients and sustainable biomaterials. Through its Chitosan Global division ( www.chitosanglobal.com ), the company serves as the official U.S. marketing arm for Promecens Entosystems. Chitosan Global represents Chitosan manufacturers from around the globe. MEDIA CONTACT: Stephen Nice President, Shield Nutraceuticals, Inc. Email: steve@shieldnutra.com Phone: 423-202-6145 Address: 2109 West Market St. Johnson City, TN 37604 BUSINESS INQUIRIES: All partnership, distribution, and product inquiries should be directed to: Steve Nice at steve@chitosanglobal.com or 423-202-6145 This press release contains forward-looking statements. Stephen Nice Shield Nutraceuticals, Inc. +1 423-202-6145 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2

30 Aug 2024

·firstwordpharma.com

NuCana halts mid-stage colorectal study of chemotherapy derivative

NuCana said Thursday that a pre-planned initial analysis of the Phase II NuTide:323 trial revealed that NUC-3373 is unlikely to meet the primary endpoint of superior progression-free survival (PFS) versus a standard-of-care drug cocktail, prompting the company to shut down the study.NUC-3373 is a derivative of the nucleoside analogue 5-fluorouracil, a commonly used chemotherapy agent. NuCana was testing its candidate in combination with leucovorin, irinotecan and Avastin (bevacizumab). The experimental regimen was being compared against a standard treatment that combines those same three drugs with5-fluorouracil. According to NuCana, there were "prognostic imbalances favouring the control arm," though the company didn't elaborate on the specific imbalances. "We gained valuable knowledge from the NuTide:323 study which will inform our ongoing development programmes," CEO Hugh Griffith said. "These results highlight the challenges associated with developing new medicines for patients with complex and heterogeneous cancers such as metastatic colorectal cancer." The firm is also testing NUC-3373 in the Phase I/II NuTide:303 trial, which is exploring a combination of the candidate with either Merck & Co.'s Keytruda (pembrolizumab) or the chemotherapy docetaxel in patients with lung cancer.NuCana's pipeline also includes NUC-7738, a derivative of cordycepin designed to have long-lasting cytotoxic activity. At the annual European Society for Medical Oncology (ESMO) meeting next month, the company plans to share data from the Phase II NuTide:701 study of the asset in combination with Keytruda in patients with melanoma.

Phase 2

08 Oct 2021

·www.ox.ac.uk

Anti-cancer drug derived from fungus shows promise in clinical trials

Oxford University researchers have worked in collaboration with industry leaders NuCana to assess a novel chemotherapy drug derived from a fungus. A study in Clinical Cancer Research has shown that the new drug NUC-7738, developed by NuCana, has a up to 40 times greater potency for killing cancer cells than its parent compound, with limited toxic side effects. The naturally-occurring nucleoside analogue known as Cordycepin (a.k.a 3’-deoxyadenosine) is found in the Himalayan fungus Cordyceps sinensis and has been used in traditional Chinese medicine for hundreds of years to treat cancers and other inflammatory diseases. However, it breaks down quickly in the blood stream, so a minimal amount of cancer-destroying drug is delivered to the tumour. In order to improve its potency and clinically assess its applications as a cancer drug, biopharmaceutical company NuCana has developed Cordycepin into a clinical therapy, using their novel ProTide technology, to create a chemotherapy drug with dramatically improved efficacy. Once inside the body, Cordycepin requires transport into cancer cells by a nucleoside transporter (hENT1), it must be converted to the active anti-cancer metabolite, known as 3’-dATP, by a phosphorylating enzyme (ADK), and it is rapidly broken down in the blood by an enzyme called ADA. Together, these resistance mechanisms associated with transport, activation and breakdown result in insufficient delivery of anti-cancer metabolite to the tumour. NuCana have utilised novel ProTide technology to design a therapy that can bypass these resistance mechanisms and generate high levels of the active anti-cancer metabolite, 3’-dATP, inside cancer cells. ProTide technology is a novel approach for delivering chemotherapy drugs into cancer cells. It works by attaching small chemical groups to nucleoside analogues like Cordycepin, which are then later metabolised once it has reached the patient’s cancer cells, releasing the activated drug. This technology has already been successfully used in the FDA approved antiviral drugs Remsidivir and Sofusbuvir to treat different viral infections such as Hepatitis C, Ebola and COVID-19. The results of the study published in Clinical Cancer Research suggest that by overcoming key cancer resistance mechanisms, NUC-7738 has greater cytotoxic activity than Cordycepin against a range of cancer cells. Oxford researchers and their collaborators in Edinburgh and Newcastle are now assessing NUC-7738 in the Phase 1 clinical trial NuTide:701, which tests the drug in patients with advanced solid tumours that were resistant to conventional treatment. Early results from the trial have shown that NUC-7738 is well tolerated by patients and shows encouraging signs of anti-cancer activity. Further Phase 2 clinical trials of this drug are now being planned in partnership with NuCana, to add to growing number of ProTide technology cancer drugs that are being developed to treat cancer. About this study This study was led by Prof Sarah Blagden and Dr Hagen Schwenzer, in partnership with NuCana via the Clinical Positioning Network: an Oxford Cancer service that partners commercial organisations with leading academics to clinical develop novel cancer diagnostics and therapeutics. Additional partners involved in this project include researchers at the Universities of St Andrew’s and Cardiff. NuCana in collaboration with a team in Cardiff University, synthesised the ProTide version of 3’-deoxyadenosine or Cordycepin called NUC-7738. ProTide technology was invented by NuCana's late Chief Scientific Officer, Professor Christopher McGuigan at Cardiff University. In vitro research was conducted at the Universities of Oxford and St Andrew’s. The clinical trial was led from the Oxford Early Phase Clinical Trials Unit, with additional recruitment in Edinburgh and Newcastle. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying ProTideTM technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogues, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and haematological tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising their proprietary technology, NuCana are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Phase 1Drug Approval

100 Deals associated with Cordycepin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Cordycepin	-	DB12156

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lymphopenia	Phase 2	China	Second Affiliated Hospital of Soochow University	01 Dec 2025
Solid tumor	Phase 2	China	Second Affiliated Hospital of Soochow University	01 Dec 2025
Advanced Malignant Solid Neoplasm	Phase 2	-	Second Affiliated Hospital of Soochow University	15 Jun 2025
TdT Positive Acute Lymphoblastic Leukemia	Phase 2	United States	OncoVista, Inc.	01 Jun 2008
Lymphoid Leukemia	Phase 2	-	Danisco Holdings (UK) Ltd.	-
Lymphoid Leukemia	Phase 2	-	National Cancer Institute	-
Lymphoid Leukemia	Phase 2	-	OncoVista Innovative Therapies, Inc.	-
disorder of aging	Preclinical	China	Beijing Normal University	04 Mar 2026
Colorectal Cancer	Preclinical	China	Chengdu Daoboqin Pharmaceutical Technology Co., Ltd.	08 Apr 2022
Stomach Cancer	Preclinical	China	Chengdu Daoboqin Pharmaceutical Technology Co., Ltd.	08 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis